I recently presented Yale Surgical Grand Rounds focused on “Cost and Quality in Cancer Care.” Amidst the talks in Washington regarding our unsustainable health care spending, and provisions of the Affordable Care Act rapidly taking hold, it seemed appropriate to start to critically evaluate how we spend our health care dollar and the value we receive in return. The data are not news to anyone. We spend more per capita than any other nation on earth, and yet the Organization for Economic Cooperation and Development (OECD) and the Commonwealth Fund find the U.S. lagging in terms of access, quality, efficiency, and equity of care. How can this be? We spend more than twice the OECD average on MRIs and CT scans, and our unabashed (and sometimes inappropriate) use of these may drive up costs without a commensurate improvement in quality despite innovations in technology.

I told the story of a very elderly patient of mine, who had gone for a routine screening mammogram, which found a speck of calcifications which were further evaluated with magnification views and a biopsy before she was referred to me with low grade DCIS for surgical considerations. We had a very frank discussion – although she was certainly healthy for her very advanced age, with hypertension as her only comorbidity, one had to wonder about the natural history of her disease and whether this would ever progress to invasive disease that would threaten her quality or quantity of life. As she contemplated whether or not to pursue surgical extirpation of her disease given our conversation, I considered why she had a screening mammogram her age, with little to no evidence of the efficacy of mammography in this population. A recent New England Journal of Medicine article noted significant overdiagnosis, and the paper published in JAMA Internal Medicine estimated annual screening related expenditures associated with mammography in the population over the age of 75 to be $410.6M.

But it’s not just the fact that our duty as citizens should force us to be good stewards of health care resources. It’s our duty as physicians to avoid needless tests that could add to potential morbidity. Beyond that, one cannot underestimate the effect of the financial impact cancer treatment on the quality of life of our patients. Bankruptcy levels continue to rise in this nation, and the #1 cause (accounting for 42% of all bankruptcies) is medical expenses — that’s more than job loss, credit card debt, avoiding foreclosure, preventing loss of utilities, student loans, and car payments combined.

We need to stop the madness –- stop ordering metastatic work-ups on patients with early stage breast cancer; stop doing routine MRIs even on patients planning to have bilateral mastectomies; stop doing a CBC and complete metabolic profile on every patient who walks into your office “just because”….we need to practice more rational evidence-based medicine; and our professional organizations like ASCO need to support these choices with guidelines like its “Top Five.” Soon after I gave the talk, a few people showed me the Time article that came out the same day. The same song, with a different verse. We can no longer choose to ignore the issue, for if we don’t step up to stop the madness, others will stop it for us.

Anees Chagpar is an oncologist who blogs at ASCO Connection, where this article originally appeared.